Oncology News | pharmaphorum

News

Y-mAbs claims FDA OK for neuroblastoma drug Danyelza

Y-mAbs Therapeutics has claimed its first product approval, getting a green light from the FDA for Danyelza for the rare cancer neuroblastoma.

News

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage devel

News

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressi

News

Roche’s Herceptin/Perjeta combo product nears EU approval

The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin and Perjeta – part of the company’s defense against Hercept

News

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare d...

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS funding of

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen combines Darzalex with COVID-19 drug in new multiple...

Janssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the FDA and EMA, hoping to give the treatment another edge over emerging comp

Y-mAbs claims FDA OK for neuroblastoma drug Danyelza

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

Roche’s Herceptin/Perjeta combo product nears EU approval

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare d...

Janssen combines Darzalex with COVID-19 drug in new multiple...

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks